Testing three drugs together for glioma that has come back
Official title: VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether a mix of three drugs can stop glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary from growing after it returns.
Read our full plain-language summary
What the trial team says
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Key facts
- Registry number
- NCT07831369
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Where it is running
This trial lists 1 site.
-
Virginia
- Inova Schar Cancer (Fairfax)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.